Abstract
Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Current Signal Transduction Therapy
Title:Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells
Volume: 8 Issue: 2
Author(s): Chao-Neng Tseng, Chung-Lung Cho, Tzan-Wen Chen, Chien-Chih Chiu, Hsueh-Wei Chang, Fang-Rong Chang and Yung-Fu Chang
Affiliation:
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Abstract: Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Export Options
About this article
Cite this article as:
Tseng Chao-Neng, Cho Chung-Lung, Chen Tzan-Wen, Chiu Chien-Chih, Chang Hsueh-Wei, Chang Fang-Rong and Chang Yung-Fu, Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660005
DOI https://dx.doi.org/10.2174/15743624113086660005 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
Call for Papers in Thematic Issues
Metabolism in Inflammation-Induced Cancer
We will talk about the primary mechanisms and principles of inflammation-induced cancer based on the most recent research findings and our understanding of the tumor development process, with an emphasis on the crosstalk between metabolism and inflammation-induced cancer. The regulatory mechanisms of T cell subpopulation differentiation, the regulatory function of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets Silicon Switches of Marketed Drugs
Mini-Reviews in Medicinal Chemistry Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design PHD3 as a Prognosis Marker and its Relationship with Immune Infiltration in Lung Adenocarcinoma
Combinatorial Chemistry & High Throughput Screening Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Anti-Cancer Agents in Medicinal Chemistry Prognostic Impact of Tissue Inhibitor of Metalloproteinase-1 in Non- Small Cell Lung Cancer: Systematic Review and Meta-Analysis
Current Medicinal Chemistry Glucuronides in Anti-Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Amalgamation of Nanotechnology for Delivery of Bioactive Constituents in Solid Tumors
Current Drug Delivery Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets GCPII Variants, Paralogs and Orthologs
Current Medicinal Chemistry The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Quinoline-based Compounds with Potential Activity against Drugresistant Cancers
Current Topics in Medicinal Chemistry Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Exploring the Chemistry and Therapeutic Potential of Triazoles: A Comprehensive Literature Review
Mini-Reviews in Medicinal Chemistry Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry